Mass Spectral Analyses of Labile DOTA-NHS and Heterogeneity Determination of DOTA or DM1 Conjugated Anti-PSMA Antibody for Prostate Cancer Therapy
Authors:
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 94 (4) , 788-797
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Anticancer AntibodiesAmerican Journal of Clinical Pathology, 2003
- Antibody-based therapeutics in oncologyExpert Review of Anticancer Therapy, 2003
- Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative StudyJournal of Clinical Oncology, 2003
- Novel Prostate-Specific Promoter Derived from PSA and PSMA EnhancersMolecular Therapy, 2002
- Anti‐tumor effects of toxins targeted to the prostate specific membrane antigenThe Prostate, 2002
- In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapyUrology, 2001
- PSMA specific antibodies and their diagnostic and therapeutic useExpert Opinion on Investigational Drugs, 2001
- Prostate-specific Membrane Antigen (PSMA)-specific Monoclonal Antibodies in the Treatment of Prostate and Other CancersCancer and Metastasis Reviews, 1999
- Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptidesThe Prostate, 1998
- Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.Proceedings of the National Academy of Sciences, 1996